INmune Bio Inc. Common stock
INMB US45782T1051
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Moss David J CFO |
5.29 USD |
10,000 Bought |
52,868 USD |
30/09/2024 | 30/09/2024 |
Tesi Raymond Joseph CEO |
6.38 USD |
15,380 Bought |
98,048 USD |
12/09/2024 | 12/09/2024 |
Moss David J CFO |
6.38 USD |
7,690 Bought |
49,024 USD |
12/09/2024 | 12/09/2024 |
Juda Scott O |
7.27 USD |
5,000 Bought |
36,350 USD |
25/06/2024 | 25/06/2024 |
Juda Scott O |
6.95 USD |
7,000 Bought |
48,650 USD |
10/11/2023 | 10/11/2023 |